Project Grant R01HL176836
Award Date
6/15/25
Completion Date
4/30/30
Dollars Obligated
$668K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This $144,989 project grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development, training, and testing of deep generative models using computed tomography (CT) images to predict lung injury progression and treatment responses for acute respiratory distress syndrome (ARDS). The awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will leverage its...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $153,099 to the Massachusetts Institute of Technology (MIT) to conduct research on treatment strategies for Acute Respiratory Distress Syndrome (ARDS). The key products and services to be delivered under this grant include: Utilizing "target trial emulation" and advanced causal inference methods to analyze observational data...
This $600,761 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the role of the NKG2D receptor and its ligands in driving lung inflammation and development of bronchopulmonary dysplasia (BPD) in preterm infants. The key objectives are to: 1) Investigate the contribution of NKG2D+ lung lymphocytes (gamma-delta T cells and NK cells) to LPS- and hyperoxia-induced lung...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $122,788 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to establish a pharmacokinetic model for absolute quantification of pulmonary perfusion and microvascular parameters and validate this model in large animal models with independent tissue analyses. The project aims to provide an improved understanding...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $708,266 to The General Hospital Corporation (doing business as Massachusetts General Hospital) from January 1, 2025 to December 31, 2028. The award supports research to determine the role of the long non-coding RNA SALTE1 in vascular aging and heart failure with preserved ejection fraction (HFPEF). The research aims to shed light on...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), totaling $645,450.00 supports research to investigate the mechanisms by which exposure to hyperoxia (supplemental oxygen) in preterm infants leads to decreased angiogenesis (blood vessel growth) and the development of bronchopulmonary dysplasia (BPD), a common complication of premature birth. The research, conducted at the Medical...
This $165,856 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 Cardiovascular Diseases Research program will fund a study to characterize current practice patterns and outcomes associated with corticosteroid therapy for acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) in critically ill patients. The study will analyze a large national cohort to 1) document corticosteroid dosing, route, timing, and duration for managing AE-IPF, and 2)...
This $1,527,766 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) seeks to develop, validate, and demonstrate the impact of a novel in-hospital mortality prediction model (MPM) that optimizes fairness across key subgroups defined by demographic and socioeconomic factors. The objectives are to: Develop fairness-informed in-hospital MPMs by identifying predictive features, assessing missing data bias, and implementing bias...
The federal Project Grant award R01HL178823, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on exploring therapeutic strategies for treating and preventing neutropenia-related bacterial pneumonia. The $676,748 award aims to increase the lifespan of neutrophils in the lungs of neutropenic patients by targeting the cell death executor Gasdermin D (GSDMD). The research seeks to uncover the underlying...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $844,386 to support research on the genetic landscape of childhood interstitial and diffuse lung diseases (CHILD). The key objectives are to: 1) Define molecular profiles of 300 CHILD lung biopsy samples to identify patient clusters with similar underlying causes, 2) Analyze whole exome sequence data from 400 children with...